Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rahul Aggarwal

Showing results (171-180 of 223) with videos related to

Pageof 23
Sort By:
Magnetic Resonance in Medicine|March 26, 2018
Technique development of 3D dynamic CS-EPSI for hyperpolarized <sup>13</sup> C pyruvate MR molecular imaging of human prostate cancerHsin-Yu Chen, Peder E Z Larson, Jeremy W Gordon, et al.
Journal of Cardiac Failure|May 13, 2024
Generalizability of the Spectrum of Kidney Risk in the FINEARTS-HF Trial to U.S. Adults With Heart FailureJohn W Ostrominski, Rahul Aggarwal, Brian L Claggett, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|September 5, 2020
The Synthesis and Structural Requirements for Measuring Glucocorticoid Receptor Expression In Vivo with (±)-<sup>11</sup>C-YJH08 PETYangjie Huang, Ning Zhao, Yung-Hua Wang, et al.
Scientific Reports|March 4, 2021
Cell-free DNA concentration and fragment size as a biomarker for prostate cancerEmmalyn Chen, Clinton L Cario, Lancelote Leong, et al.
Magnetic Resonance in Medicine|August 10, 2021
Clinical translation of hyperpolarized <sup>13</sup> C pyruvate and urea MRI for simultaneous metabolic and perfusion imagingHecong Qin, Shuyu Tang, Andrew M Riselli, et al.
Journal of the National Cancer Institute|December 6, 2017
Concordance of Circulating Tumor DNA and Matched Metastatic Tissue Biopsy in Prostate CancerAlexander W Wyatt, Matti Annala, Rahul Aggarwal, et al.
British Journal of Cancer|November 19, 2023
Phase 1b study of enzalutamide plus CC-115, a dual mTORC1/2 and DNA-PK inhibitor, in men with metastatic castration-resistant prostate cancer (mCRPC)Jimmy L Zhao, Emmanuel S Antonarakis, Heather H Cheng, et al.
Frontiers in Oncology|April 24, 2023
Somatic alterations of <i>TP53</i> and <i>MDM2</i> associated with response to enfortumab vedotin in patients with advanced urothelial cancerTanya Jindal, Xiaolin Zhu, Rohit Bose, et al.
Prostate Cancer and Prostatic Diseases|March 31, 2025
Racial variation in the advanced prostate cancer genomeEmily M Feng, Jenny Vo-Phamhi, Aishwarya N Subramanian, et al.
NPJ Genomic Medicine|September 22, 2021
Predicting cancer drug TARGETS - TreAtment Response Generalized Elastic-neT SignaturesNicholas R Rydzewski, Erik Peterson, Joshua M Lang, et al.
Pageof 23

Showing results (171-180 of 223) with videos related to

Sort By:
Pageof 23
Magnetic Resonance in Medicine|March 26, 2018
Technique development of 3D dynamic CS-EPSI for hyperpolarized <sup>13</sup> C pyruvate MR molecular imaging of human prostate cancerHsin-Yu Chen, Peder E Z Larson, Jeremy W Gordon, et al.
Journal of Cardiac Failure|May 13, 2024
Generalizability of the Spectrum of Kidney Risk in the FINEARTS-HF Trial to U.S. Adults With Heart FailureJohn W Ostrominski, Rahul Aggarwal, Brian L Claggett, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|September 5, 2020
The Synthesis and Structural Requirements for Measuring Glucocorticoid Receptor Expression In Vivo with (±)-<sup>11</sup>C-YJH08 PETYangjie Huang, Ning Zhao, Yung-Hua Wang, et al.
Scientific Reports|March 4, 2021
Cell-free DNA concentration and fragment size as a biomarker for prostate cancerEmmalyn Chen, Clinton L Cario, Lancelote Leong, et al.
Magnetic Resonance in Medicine|August 10, 2021
Clinical translation of hyperpolarized <sup>13</sup> C pyruvate and urea MRI for simultaneous metabolic and perfusion imagingHecong Qin, Shuyu Tang, Andrew M Riselli, et al.
Journal of the National Cancer Institute|December 6, 2017
Concordance of Circulating Tumor DNA and Matched Metastatic Tissue Biopsy in Prostate CancerAlexander W Wyatt, Matti Annala, Rahul Aggarwal, et al.
British Journal of Cancer|November 19, 2023
Phase 1b study of enzalutamide plus CC-115, a dual mTORC1/2 and DNA-PK inhibitor, in men with metastatic castration-resistant prostate cancer (mCRPC)Jimmy L Zhao, Emmanuel S Antonarakis, Heather H Cheng, et al.
Frontiers in Oncology|April 24, 2023
Somatic alterations of <i>TP53</i> and <i>MDM2</i> associated with response to enfortumab vedotin in patients with advanced urothelial cancerTanya Jindal, Xiaolin Zhu, Rohit Bose, et al.
Prostate Cancer and Prostatic Diseases|March 31, 2025
Racial variation in the advanced prostate cancer genomeEmily M Feng, Jenny Vo-Phamhi, Aishwarya N Subramanian, et al.
NPJ Genomic Medicine|September 22, 2021
Predicting cancer drug TARGETS - TreAtment Response Generalized Elastic-neT SignaturesNicholas R Rydzewski, Erik Peterson, Joshua M Lang, et al.
Pageof 23